

An Intensive Workshop on Antiretroviral Strategies: New Drugs, Antiretroviral Failure, and Resistance Testing

Washington, DC

Thursday, May 7, 2009
1:00 PM – 4:30 PM

JW Marriott Hotel Pennsylvania Avenue
Justice Room, Meeting Room Level
1331 Pennsylvania Avenue
Washington, DC 20004

Workshop Faculty

Joel E. Gallant, MD, MPH
Professor of Medicine and Epidemiology
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Associate Director
Johns Hopkins AIDS Service
Baltimore, Maryland

Daniel R. Kuritzkes, MD
Professor of Medicine
Harvard Medical School
Director of AIDS Research
Brigham and Women's Hospital
Cambridge, Massachusetts

Who Should Attend

Experienced HIV clinical decision makers (physicians, nurse practitioners, physician assistants) caring for HIV patients with a working knowledge of HIV disease management.

Overview and Assessment of Needs

Expert faculty will speak in a small-group interactive setting on timely and clinically relevant issues in HIV disease management such as:

- Management strategies for antiretroviral failure
- Role of resistance testing to determine treatment options for patients with multiple drug resistance mutations
- Role of new drugs in failure regimens

Rapid advances in these areas require the ongoing attention of practitioners involved in HIV medicine. The course will address the implications of this information on strategies for antiretroviral therapy.

Learning Objectives

Upon completion of the workshop, participants will be able to:

- Design appropriate treatment strategies for patients experiencing antiretroviral failure that consider current data on new drugs, new classes, and new assays
- Identify the elements of an effective salvage regimen
- Compare and contrast the benefits and limitations of genotypes and phenotypes
- Explain the effective use of tropism assays and how they may fit into the management of HIV-infected patients
- Examine the risk and activity and the resistance profiles of new and emerging antiretroviral drugs

CME Accreditation Statement

The International AIDS Society–USA is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

Credit Designation Statement

The International AIDS Society–USA designates this educational activity for a maximum of 3.25 *AMA PRA Category 1 Credits*.™ Physicians should only claim credit commensurate with the extent of their participation in the activity.

Conflicts of Interest

Information regarding conflicts of interest is obtained from all parties with control over the activity content (ie, Board of Directors, workshop development committee, workshop leaders, and IAS-USA staff), and any conflicts of interest of those parties are resolved prior to the activity being delivered.

Registration

The registration fee is \$30. Fax or mail your complete registration form (below) with payment. Registration closes April 30, 2009. Registrations will be accepted on a first-come, first-served basis. Attendance is limited to 30 participants. Forms should be mailed or faxed to:

International AIDS Society-USA
425 California Street, Suite 1450
San Francisco, CA 94104-2120
Tel: 415-544-9400
Fax: 415-544-9402

Funding

This activity is made possible by educational grants from several commercial companies that are committed to supporting independent CME in the field of HIV/AIDS. Major grant support has been provided by: Bristol-Myers Squibb, Pfizer Global Pharmaceuticals, and Merck & Co., Inc.

+ + +

